Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nepstar Acquires 18 Chain Drugstores

This article was originally published in PharmAsia News

Executive Summary

After purchasing 68 drugstores in February, Nepstar has made its second acquisition after listing overseas, buying Huirentang's 18 chain drugstores in Dongguan, Guangdong province, for 2.3 million yuan ($324,373). Nepstar will speed up its merger and acquisition activities this year, targeting the opening of 1,050 new shops, especially in the Zhujiang Delta area. According to the company's listing plan, funds raised will be channeled into the setup of a distribution center, an enterprise resource planning system and chain drugstore expansion; inside sources revealed that the capital will be mainly used to increase the number of shops, particularly in high entry-level cities such as Beijing and Shanghai. The firm recently invested substantially in a new SAP ERP system. (Click here for more - Chinese Language)

You may also be interested in...

Sandoz Hits Back At Biosimilar Misinformation

Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.

Spanish Consumer Health And Cosmetics Firms Eying Up China’s Online Self-Care Market

A recent Spanish self-care and cosmetics industry conference organized by ANEFP and Beauty Cluster explores the commercial opportunity in China via online marketplace Tmall. 

NeuClone Makes Progress On Ustekinumab

Australia’s NeuClone expects to be among the first biosimilar market entrants to challenge Stelara, with the firm’s NeuLara ustekinumab rival reporting positive Phase I data as the company prepares to move ahead with Phase III trials next year.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts